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Abstract
Hepatic encephalopathy (HE) is a major complication that develops in some form and at
some stage in a majority of patients with liver cirrhosis. Overt HE occurs in approximately
30–45% of cirrhotic patients. Minimal HE (MHE), the mildest form of HE, is characterized
by subtle motor and cognitive deficits and impairs health-related quality of life. The Indian
National Association for Study of the Liver (INASL) set up a Working Party on MHE in
2008 with a mandate to develop consensus guidelines on various aspects of MHE relevant
to clinical practice. Questions related to the definition of MHE, its prevalence, diagnosis,
clinical characteristics, pathogenesis, natural history and treatment were addressed by the
members of the Working Party.
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1. Introduction
Hepatic encephalopathy (HE) is a major complication that devel-
ops in some form and at some stage in a majority of patients with
liver cirrhosis. Overt HE occurs in approximately 30–45% of
cirrhotic patients2,3 and in 10–50% of patients with transjugular
intrahepatic portosystemic shunt (TIPS).1 Minimal HE (MHE), the
mildest form of HE, is characterized by subtle motor and cognitive
deficits, and impairs health-related quality of life (HRQOL).2–4
The Indian National Association for Study of the Liver (INASL)
set up a Working Party on MHE in 2008 with a mandate to develop
consensus guidelines on various aspects of MHE relevant to clini-
cal practice; its final report was presented at the annual meeting of
the INASL on 28 March 2009. This is the first-ever Consensus
Statement developed on this subject.
The following questions were addressed by the Working Party.
Definition: What is the most appropriate definition of MHE? Is
there a need to broaden the definition to include liver diseases and
causes of portal hypertension other than cirrhosis? (Discussion led
by Dr Deepak Amarapurkar.)
Prevalence: What is the overall prevalence of MHE? What are
the risk factors that influence its prevalence? Does it interfere with
patients’ HRQOL? What is the associated economic burden of
MHE? (Discussion led by Dr Avnish K. Seth and Dr Ramesh R.
Rai.)
Diagnosis: How can we differentiate grade 0 from grade 1 HE?
What are the roles for neuropsychological and neurophysiological
testing and current neuroimaging techniques in the diagnosis of
MHE? (Discussion led by Dr Vivek A. Saraswat, Dr Barjesh K.
Sharma and Dr Rakesh K. Gupta.)
Clinical characteristics: Is MHE a ‘symptomatic’ condition? If
so, what are the cognitive symptoms? Should all cirrhotic patients
be subjected to testing for the diagnosis of MHE or should it be
restricted to patients with cognitive symptoms? (Discussion led by
Dr Vivek A. Saraswat and Dr Samir Shah.)
Pathogenesis: What is the role of ammonia, intestinal flora and
inflammation in the pathogenesis of MHE? (Discussion led by Dr
Yogesh K. Chawla, Dr Praveen Sharma and Dr Kaushal Madan.)
Natural history: Does MHE predict overt HE and poor
outcome? (Discussion led by Dr Rakesh Aggarwal.)
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Treatment: What is the role of non-absorbable disaccharides,
pre and/or probiotic, L-ornithine–L-aspartate (LOLA), or antibi-
otics in the treatment of MHE? Does treatment improve HRQOL?
(Discussion led by Dr Radha K. Dhiman, Dr Ajay Duseja and Dr
Shiv K. Sarin.)
Dr Roger Butterworth, Dr Subrat K. Acharya, Dr Abraham
Koshy, Dr Sri Prakash Mishra and Dr Jang B. Dilawari were
special invitees and actively participated in the entire discussion.
1.1 Quality of evidence on which a
recommendation is based
The Working Party adopted the use of the Oxford system for
developing an evidence-based approach. The group assessed the
level of existing evidence and accordingly ranked the recommen-
dations, i.e. level of evidence from 1 (highest) to 5 (lowest); grade
of recommendation from A (strongest) to D (weakest).5
2. Definition
The Working Party on Hepatic Encephalopathy convened by the
Organisation Mondiale de Gastroenterologie presented its delib-
erations at the 11th World Congress of Gastroenterology, Vienna
(1998). It defined HE as a spectrum of neuropsychiatric abnor-
malities seen in patients with liver dysfunction, after exclusion of
other known brain diseases, and proposed new nomenclature with
respect to: (i) the nature of the hepatic abnormality; and (ii) the
duration and characteristics of the neurological manifestations,
broadly categorizing HE into three types (Table 1).2,6 MHE was
included as the third and final category of type B and C HE.
Although implicit in the Vienna definition, the increasing recog-
nition of MHE in non-cirrhotic liver diseases such as non-cirrhotic
portal fibrosis,7 extrahepatic portal venous obstruction
(EHPVO)8–10 and acute viral hepatitis11 warrants their explicit
inclusion in the definition of MHE. The INASL Working Party
recommended broadening the definition of MHE to include liver
diseases and causes of portal hypertension other than cirrhosis and
also to include mention of neuropsychometric or neurophysiologi-
cal tests, which can be performed in the outpatient setting, for
diagnosis of MHE.
Consensus statement
1 MHE may be defined as the presence of measurable cogni-
tive defects in patients with liver disease and/ or portal-
systemic shunting, that are not identified by detailed clinical
history and complete neurological examination, including
interview of close family members, but are detected by
abnormalities in neuropsychometric or neurophysiological
tests that can be performed at the bedside and in the out-
patient setting, in the absence of other known causes of
abnormal cognitive tests. (5, D)
3. Prevalence
3.1. Prevalence of MHE among cirrhotic and
noncirrhotic patients
The true prevalence of MHE in patients with portal hypertension is
unknown. Though MHE has traditionally been diagnosed in
patients with cirrhosis of the liver, impairment of cognitive func-
tion has also been demonstrated in patients with noncirrhotic
portal hypertension.7–10 Prevalence of MHE has been reported to
vary between 22% and 74% in patients with cirrhosis of the
liver,3,4,12–22 depending on both the examinable dimensions of the
disease and fixed diagnostic cut-offs. The range of diagnostic
criteria used in these studies included: neuropsychological tests in
different combinations with different cut-offs (abnormal scores >2
standard deviation [SD] or >1 SD below mean),3,4,12–19,21 short
neuropsychological batteries (Psychometric Hepatic Encephal-
opathy Score [PHES]),20,22 various computerized tests including
critical clicker frequency (CFF)19,20,22 and inhibitory control test
(ICT),21 neurophysiological tests with different cut-off (electroen-
cephalography [EEG], P300 evoked responses),12–14,16,17 or their
combinations.
Table 1 Nomenclature of hepatic encephalopathy (HE)
Type Description Category (by duration
and characteristics)
Subcategory (by duration
and characteristics)
A (Acute liver failure) HE associated with acute liver failure Not applicable Not applicable
B (Bypass) HE associated with portosystemic bypass
and no intrinsic hepatocellular disease
⎤
⎦
⎥⎥⎥⎥
Episodic
Persistent
Minimal
Precipitated
Spontaneous
Recurrent
Mild
Severe
Treatment-dependent
Not applicable
C (Cirrhosis) HE associated with cirrhosis and portal
hypertension or portosystemic shunts
Adapted from Mullen KD6
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The reasons for large variations in the prevalence of MHE
among different studies are also related to prior episodes of overt
HE,14 severity of liver disease,4,13–16,18,22 age,13,16,22 presence of
esophageal varices,14 and surgical porto-systemic shunts.5 Cause
of liver disease does not affect the prevalence rate of MHE.12,13,16,18
There are no data on prevalence of MHE in patients who have
undergone TIPS.
Consensus statement
2 Prevalence of MHE among patients with cirrhosis without
overt HE is high. (1b)
3 Variability in diagnostic criteria used for MHE affects its
prevalence rate. (1b)
4 Use of age- and education-adjusted cut-offs for neuropsy-
chological tests may reduce variability in prevalence rates.
(3a)
5 Prevalence of MHE increases with increasing severity of
liver disease. (3b)
6 Prevalence of MHE is not affected by etiology once patients
with recent alcohol intake are excluded. (3b)
7 MHE is present in a significant proportion of patients with
portal hypertension without intrinsic liver disease. Further
studies are required on this subject. (3b, B)
8 Prevalence of MHE has not been studied systematically in
patients who have undergone TIPS. Further studies are
required on this subject. (5, D)
3.2. Health-related quality of life
3.2.1. Effect of MHE on daily functioning
MHE is associated with cognitive impairment that may have a
detrimental effect on HRQOL.3,23,24 It mainly affects complex
activities involving attention, information processing and psycho-
motor skills such as driving a car, planning a trip, etc. whereas
basic activities of daily life, such as shopping, dressing, personal
hygiene, etc. are preserved. Two studies demonstrated that
patients with MHE had a significant impairment of daily func-
tioning, such as social interaction, alertness, emotional behavior,
sleep, work, home management, recreation and pastimes com-
pared with cirrhotic patients who did not have MHE.3,23 Treat-
ment with lactulose improved both cognitive functions and
HRQOL; improvement in the latter was linked to improvement
in cognitive function.3
3.2.2. Effect of MHE on driving
Schomerus et al.25 were the first to demonstrate a negative effect of
psychomotor deficits in patients with MHE on driving fitness in 40
patients with liver cirrhosis, 60% of whom were considered unfit
to drive on the basis of performance on psychometric testing.
However, these authors did not elaborate on the methods applied
for assessing driving fitness. Although similar results were
reported by Watanabe et al.,26 a pilot study that evaluated driving
in a real road test in nine patients with cirrhosis and MHE did not
find impaired driving performance.27 In a recent landmark study,
Wein and colleagues28 used a standardized 90-minute on-road
driving test and found that the fitness to drive a car was impaired
in cirrhotic patients with MHE. Increased risk of automobile acci-
dents was related to a decline in cognitive function.29 Impairment
in attention and speed of mental processing adversely affects an
individual’s ability to react to unexpected traffic conditions, such
as an illegal incursion by another vehicle at an intersection. Bajaj
et al.30 found a higher self-reported rate of traffic violations and
accidents in cirrhotic patients with MHE compared to controls.
They also demonstrated a significantly higher rate of motor vehicle
crashes over the preceding year in patients with MHE compared to
patients without MHE,31 which was defined by the ICT, a test of
response inhibition and executive control. A recent report deter-
mined that cirrhotics with MHE had a significantly higher crash
rate over the preceding year as well as on prospective follow up,
compared to patients without MHE, using self-reports and Depart-
ment of Transportation reports.32 Patients with MHE also had
impaired navigation skills.33 Navigation, required for safe driving,
is a complex process that depends on functioning working
memory, attention, and speed of mental processing; impairment in
navigation skills correlated with impairment in response inhibition
and attention.
3.3. Economic burden of MHE
Although some data are available for HE, the economic burden
associated with MHE has not been assessed.1 In the USA in 2003,
estimated total charges for hospitalizations related to HE were
over $US930m. Total charges for unspecified encephalopathy,
portal hypertension, and alcoholic and non-alcoholic cirrhosis
were approximately $US268m, $US90m and $US3.3bn, respec-
tively.1 The impact of MHE on daily life is enormous; half of the
patients with MHE do not have regular employment, compared to
15% of patients without MHE.14 Blue-collar workers with liver
cirrhosis and MHE are less likely to earn their wages than white-
collar workers with MHE; 60% of ‘blue collar’ workers were unfit
to work compared with 20% of ‘white collar’ workers.24 Dimin-
ished work performance and lost wages also entail substantial
costs. Socioeconomic implications of the profound negative
effects of MHE on functioning in the workplace are significant.
Consensus statement
9 MHE adversely affects HRQOL. (1b)
10 MHE adversely affects driving skills. (1b)
11 Patients with MHE have higher rates of traffic violations
and motor vehicle accidents. (1b)
12 Studies are needed to fully evaluate the direct and indirect
costs related to MHE. (5D)
4. Diagnosis
4.1. Differentiation of grade 0 from grade 1 HE
The diagnosis of MHE rests on: (i) the presence of a disease that
can cause MHE, such as, cirrhosis and/or the presence of a portal-
systemic shunt (Table 1); (ii) normal mental status on clinical
examination; (iii) demonstration of abnormalities of cognition
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and/or neurophysiological variables; and (iv) exclusion of con-
comitant neurological disorders. HE is traditionally classified into
four grades according to the West Haven criteria (Table 2).1,2
However, assignment of patients with cirrhosis to HE stages 0–2
relies strongly on the subjective impression of a physician, which
does not invalidate the scale in individual cases, but may cause
discrepancies between different observers and affect the results of
multicenter trials. Reliability of the West Haven scale can be
improved by combining it with the Mini-Mental State Examina-
tion (MMSE).34
The MMSE assesses mental status systematically and thor-
oughly in only 5–10 min. It is an 11-question measure that tests
five areas of cognitive function: orientation, registration, attention
and calculation, recall and language.34 The maximum score on
MMSE is 30; a score of 23 or lower is indicative of cognitive
impairment and clinically overt HE. All high-quality studies on
MHE included MMSE as a screening test before administering
diagnostic tests for MHE.3,21,22,31–33
Consensus statement
13 HE should be graded according to West Haven criteria. (1b,
A)
14 The reliability of the West Haven scale can be improved by
combining its use with the MMSE. (1b, A)
15 The MMSE should be performed to exclude overt cognitive
impairment in all patients before formal test(s) for the diag-
nosis of MHE is/are administered. (1b, A)
4.2. Diagnostic methods
Various tools have been evaluated for the diagnosis of MHE and
include neuropsychological tests, computerized tests, short neu-
ropsychological and computerized test batteries and neurophysi-
ological tests (Table 3).35
4.2.1. Standard neuropsychological assessment
Neuropsychological tests are established, time-tested and
domains of cognitive functioning tested by particular tests are
well-characterized. However, these are time-consuming, and their
results are influenced by age and educational status. Determining
impairment in performance using age- and education-adjusted
values of at least two of the following tests is recommended:
number connection test-A (NCT-A) or figure connection test-A
(FCT-A), number connection test-B (NCT-B), block design test
and digit symbol test.2 FCT-A and figure connection test-B
(FCT-B) can replace NCT-A and NCT-B, respectively, if there are
linguistic or illiteracy concerns.9–11,19,22,38 FCT-A and -B are uni-
versally applicable tests to assess the mental state that transcend
the barriers of linguistic differences and illiteracy. Clinical signifi-
cance of these tests has been evaluated in a large number of healthy
volunteers and patients with MHE.38
4.2.2. Psychometric Hepatic Encephalopathy Score
The PHES, a standardized test battery including NCT-A and B, the
line-tracing test for time (t) and error (e), the serial-dotting test,
Table 2 West Haven criteria for semiquantitative grading of mental
state
Grade 0 Lack of detectable changes in personality or behavior
No asterixis
Grade 1 Trivial lack of awareness
Euphoria or anxiety
Shortened attention span
Impaired performance of addition
Asterixis may be present
Grade 2 Lethargy or apathy
Minimal disorientation for time or place
Subtle personality change
Inappropriate behavior, slurred speech
Impaired performance of subtraction
Asterixis is present
Grade 3 Somnolence to semi-stupor, but responsive to verbal
stimuli
Confusion
Gross disorientation
Asterixis is usually absent
Grade 4 Coma (unresponsive to verbal or noxious stimuli)
Adapted from Mullen KD6
Table 3 Diagnostic methods for the detection of minimal hepatic encephalopathy
Methods Advantages Disadvantages Feasibility to administer
in office setting
Expert neuropsychological
assessment with series of tests
Time-tested with well-recognized
clinical significance, established
Time-consuming if large number of
tests are selected
Yes
Short neuropsychological battery
(PHES)
High sensitivity with
well-recognized clinical
significance, rapid results
Limited access, limited data of
normative values
Yes
Neurophysiological tests (EEG,
spectral EEG, P300 evoked
potentials)
Objective tests, allow for objective
repeat testing
Require sophisticated equipment,
limited data
No
Computerized test (CFF, ICT,
reaction times, etc.)
Rapid tests, easy to apply Requires highly functional patients
and familiarity with computers.
Needs standardization in
different populations
Yes
CFF, critical flicker frequency; EEG, electroencephalogram; ICT, inhibitory control test; PHES, Psychometric Hepatic Encephalopathy Score.
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and the digit symbol test, has been extensively validated in the
Spanish, German and Indian populations and can be performed in
15–20 min.20,22,36,37 This battery examines many of the abnormali-
ties seen in patients with MHE, including motor speed and
accuracy, visuo-spatial orientation, visual perception, visual con-
struction, attention, concentration, and, to a lesser extent, memory.
PHES has a prognostic value for the occurrence of bouts of overt
HE and mortality in cirrhotic patients.20,22 In an Indian version,
NCT-B has been replaced by the FCT-A because of concerns that
some patients may be unfamiliar with English alphabets and hence
unable to complete NCT-B.38
Consensus statement
16 Standard neuropsychological assessment is a time-tested
and established methodology for measuring cognitive
impairment in patients with MHE. (1b)
17 Use of age- and education-adjusted values of at least two of
the following tests are recommended for the diagnosis of
MHE: NCT-A or FCT-A, NCT-B or FCT-B, block design
test and digit symbol test. (1b, A)
18 The PHES, which measures multiple domains of cognitive
function, is a reliable test battery for the assessment of
cognitive impairment in patients with MHE. (1b)
19 The PHES has a prognostic value in predicting survival.
(3b)
20 Use of age- and education-adjusted PHES is recommended
for diagnosing and monitoring MHE. (1b, A)
4.2.3. Neurophysiological tests
Changes in EEG/evoked responses are non-specific. Among EEG
variations, the most sensitive test is computer-assisted analysis,
including the mean dominant EEG frequency and the power of a
particular rhythm.39–41 Quantified-EEG has a prognostic value for
occurrence of bouts of overt HE and mortality in cirrhotic
patients.41 Among evoked responses, the P300 peak obtained in an
auditory oddball paradigm is the most sensitive test.17,42–45 These
tests can supplement neurological or neuropsychiatric examina-
tion. Saxena et al.17 demonstrated that there was a greater likeli-
hood of development of overt HE in cirrhotic patients with
abnormal P300 event-related potential latencies and NCT than in
patients with no such abnormality. Neurophysiological tests can be
used during follow up to demonstrate change in a patient’s condi-
tion. Their major limitations are: (i) need for specialized equip-
ment and technical expertise for evaluation and interpretation; and
(ii) inability to perform these tests in an outpatient clinic.
4.2.4. Critical flicker frequency
The CFF threshold measures visual discrimination and general
arousal.46 Two recent studies evaluated its usefulness in the diag-
nosis of MHE.19,20 Both studies have demonstrated that it is a
simple, reliable, and accurate method for the diagnosis of MHE.
The technique shows little dependence on age, education or train-
ing. However, one study showed that CFF decreases as age
advances, and therefore age-adjusted values may be required.22
4.2.5. Inhibitory control test
The ICT is a computerized test of response inhibition, attention
and working memory, consisting of presentation of several letters
at 500-ms intervals. This test has been used to characterize atten-
tion deficit disorder, schizophrenia and traumatic brain injury. It
has been validated for the diagnosis and follow up of MHE in the
USA, and has been found to be sensitive and reliable for this
purpose.21,47 However, it requires that the subject be familiar with
the use of computers and needs to be validated in other popula-
tions. ICT, but not standard neuropsychological tests performance,
is significantly associated with prior and future vehicle crashes and
traffic violations.32
Consensus statement
21 EEG can diagnose MHE and predicts development of overt
HE and mortality. (1b)
22 EEG requires technical expertise for evaluation and inter-
pretation. (1b)
23 P300 event-related potential can diagnose MHE, but
requires a trained person and specialized equipment. (1b)
24 EEG and P300 are difficult to use for diagnosis of MHE in
an outpatient setting. (1b, A)
25 The CFF is a simple tool for diagnosing MHE in an out-
patient setting. (1b, A)
26 The CFF predicts the development of overt HE. (1b)
27 More data are required on effect of age and education on
CFF and need for adjusted CFF cut-offs. (5, D)
28 The ICT is reliable and sensitive for the detection as well as
follow up of MHE patients. (1b, A)
29 The ICT requires highly functional patients and familiarity
with computers. (1b, A)
30 The ICT may need validation and standardization in each
population before it can be used effectively (5, D)
4.2.6. Magnetic resonance imaging and spectroscopy
Magnetic resonance imaging (MRI) has revealed alterations in
basal ganglia of patients with cirrhosis. High-signal abnormalities
on T1-weighted images in the globus pallidum have been observed
in these patients, even without clinical evidence of HE.48,49
Although various causes have been proposed50 for this hyperinten-
sity, deposition of manganese is regarded as the most likely
explanation.51 There is no direct correlation between pallidal
hyperintensity and grade of encephalopathy.52 Basal ganglion
T1-weighted signal intensity and manganese accumulation appear
to be related to the underlying degree of portal-systemic shunting
rather than directly to neuropsychiatric impairment.53 Hyperin-
tense globus pallidus on MRI is common in patients with liver
cirrhosis and also occurs in patients with noncirrhotic portal
hypertension.54
Magnetic resonance spectroscopy (MRS) shows a decrease in
myo-inositol/creatine and choline/creatine ratios in the white
matter with an increase in the Glx (glutamine and glutamate)
concentration in the basal ganglia in patients with MHE.55,56 Liver
transplantation as well as lactulose therapy have been shown to
reverse these changes at 4 weeks and later after transplantation.55
However, the ability of MRS to differentiate between cirrhotic
patients without HE and those with MHE has not been conclu-
sively shown.
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Diffusion-weighted imaging allows assessment of intracellular
and extracellular water content in the brain, which helps in differ-
entiating cytotoxic from vasogenic edema.57,58 Diffusion tensor
imaging has revealed that mean diffusivity, a measure of water
movement across cell membranes, is significantly higher in
patients with MHE in the regions of the corpus callosum, right
internal capsule, left internal capsule, caudate nuclei and occipital
white matter. Increase in mean diffusivity indicates the presence of
interstitial brain edema. Mean diffusivity values increase as the
grade of HE increases, suggesting that brain edema present in
patients with HE may contribute to its pathogenesis.59 Mean dif-
fusivity values decreased significantly and there was a correspond-
ing improvement in neuropsychological test scores in patients with
MHE after three weeks of lactulose therapy.59 MR imaging tech-
niques therefore complement neuropsychological evaluation of
MHE.
Consensus statement
31 MRS, diffusion-weighted imaging, magnetization transfer
imaging and diffusion tensor imaging show abnormalities
in cirrhotic patients with or without HE. (1b)
32 These techniques may be well suited for evaluating the
efficacy of therapeutic interventions. (1b, A)
33 These imaging techniques are currently not considered as
diagnostic modalities for MHE. (5,D)
5. Clinical characteristics
5.1. Is MHE a ‘symptomatic’ condition?
By definition, patients with MHE have a normal neurological
examination; however they may still be symptomatic. Symptoms
relate to disturbances in sleep, memory, attention, concentration
and other areas of cognition.60,61 Sleep disturbance is a classic sign
of HE. On a sleep questionnaire, disturbance is seen in 47% of
cirrhotics and 38% of patients with chronic renal failure compared
to 4.5% of controls.60 Studies using HRQOL questionnaires have
confirmed a higher frequency of sleep disturbance in cirrhotic
patients with MHE as well.3,14 However, sleep disturbance in cir-
rhosis is not associated with cognitive impairment; thus it may not
truly be an MHE symptom. Unsatisfactory sleep is associated with
higher scores for depression and anxiety, raising the possibility
that the effects of chronic disease may underlie the pathogenesis of
sleep disturbance. Disturbances in cirrhotics may also be related to
abnormalities of circadian rhythm.
Defective memory has also been shown to be a feature of MHE.
Weissenborn et al.61 have shown that patients with MHE have
impaired short- and long-term memory. This impairment was pre-
dominantly related to deficits in attention and visual perception.
Memory deficit of MHE seems to comprise short-term but not
long-term memory impairment. This can be described as an encod-
ing defect, in which memory recall (or retrieval) is intact.
5.2. What are the cognitive symptoms?
Several cognitive statements (i.e. complaints), have predictive
value for MHE, including impaired psychomotor performance (‘I
have difficulty doing handwork; I am not working at all’);
impaired sleep or rest (‘I spend much of the day lying down in
order to rest’); decreased attention (‘I am confused and start
several actions at a time’); and poor memory (‘I forget a lot; for
example, things that happened recently, where I put things, etc.’).14
5.3. Should all cirrhotic patients be subjected
to testing for the diagnosis of MHE?
It has been shown conclusively that cognitive functions improve
with therapy for MHE.3,62–67 Such therapy may improve HRQOL
of patients with MHE3,67 and delay the development of HE.68
Hence all patients with liver cirrhosis should be subjected to
testing for MHE. Special attention should be given to those who
have cognitive symptoms and high-risk groups such as active
drivers, patients handling heavy machines or reporting decline in
work performance.
Consensus statement
34 Symptoms related to sleep disturbance, memory, and atten-
tion may be elicited or may be a presenting complaint in
cirrhotic patients with MHE. (3b)
35 Cognitive functions and HRQOL improve with therapy.
Hence all patients with cirrhosis of the liver should be
tested for the presence of MHE. (1b, A)
36 Special attention should be given to those who have cog-
nitive symptoms and high-risk groups such as active
drivers, patients handling heavy machines or those report-
ing a decline in work performance. (5,D)
6. Pathogenesis
6.1. Ammonia, intestinal flora and
inflammation
Ammonia, which is primarily produced in the gut, plays a key role
in the pathogenesis of HE. In the brain, ammonia is metabolized in
astrocytes, the only cell in the brain containing the enzyme
glutamine synthetase that metabolizes ammonia. Astrocytes also
provide physical and nutritional support for neurons, maintain the
integrity of the blood–brain barrier and regulate cerebral blood
flow.69 Using positron emission tomography with 13N-ammonia,
Lockwood et al. provided direct evidence showing that ammonia
is taken up by the brain in patients with liver disease and hyper-
ammonemia.70 Ammonia also modulates glutamate neurotrans-
mission71 and induces neurosteroid production in neurons, leading
to a positive modulatory effect on the gamma-aminobutyric acid-A
receptor.72 Although the precise molecular mechanism(s) respon-
sible for neurological alteration in HE is/are not known, several
alterations in the expression of astrocytic and neuronal genes that
code for various proteins have been shown; these changes may
play a critical role in central nervous system function, including
maintenance of cell volume and neurotransmission.73,74
Animal models of MHE have been developed. These include the
end-to-side portacaval-shunted rat and the rat with graded portal
vein ligation.75 These models recapitulate several characteristic
features of MHE including moderate hyperammonemia, manga-
nese accumulation in basal ganglia,53 alterations of day–night and
circadian rhythms76 and changes in glutamate,77 monoamine,78
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opioid79 and histamine80 neurotransmission comparable to those
described in cirrhotic patients. Decreased cortical activation has
also been described in both experimental and human MHE.81
Lockwood et al.81 showed that both the cerebral metabolic rate for
ammonia and the permeability-surface area product for ammonia
were significantly higher in patients with MHE than in controls.
The increased permeability-surface area product of the blood–
brain barrier permits ammonia to diffuse across the blood–brain
barrier into the brain more freely than normal. This may cause
ammonia-induced encephalopathy even though arterial ammonia
levels are normal or near normal. Accumulation of glutamine
induces osmotic stress and leads to swelling of astrocyte. Using
magnetic resonance imaging, Cordoba et al.82 demonstrated an
increase in brain water in patients with MHE as indicated by a
decrease in magnetization transfer ratio (MTR). This was shown to
correlate with neuropsychological function, and the abnormality
was reversed by liver transplantation.82 More recently, hyperam-
monemia induced by oral administration of an amino acid solution
to patients with cirrhosis was shown to result in significant dete-
rioration in neuropsychological function, an increase in brain
glutamine levels and a reduction in the MTR, suggesting an
increase in brain water.83 This study provided further support for
the ammonia-glutamine brain water hypothesis of HE. The effect
of hyperammonemia is likely to be determined by the ability of the
astrocytes to maintain osmotic equilibrium by losing osmolytes
such as myo-inositol in response to the ammonia-induced increase
in glutamine.84
6.2. Inflammation
It has been observed that severity of MHE may not correlate with
severity of liver disease or the level of ammonia, suggesting pres-
ence of other pathogenic influences. Inflammation is one such
factor that may contribute to the development of MHE and its
progression to overt HE.85 A recent study found that severity of
MHE was independent of severity of liver disease and levels of
blood ammonia but markers of inflammation were significantly
higher in those with MHE compared to those without MHE.86
Induction of hyperammonemia led to deterioration in one or more
neuropsychological tests in 73.3%, which was significantly greater
in those with more marked inflammation, that is, higher neutrophil
counts, C-reactive protein levels, and interleukin-6 levels. These
two studies suggest that inflammation plays a synergistic role with
ammonia in producing and modulating MHE.
6.3. Intestinal Flora
Another link between inflammation, ammonia and MHE is
through gut flora and endotoxins. Indeed, lactulose, the most com-
monly used standard therapy for HE, works in part by altering gut
flora to decrease ammonia production and absorption. Zhao et al.87
demonstrated varying degrees of imbalance of intestinal flora
among cirrhotics compared to normal healthy controls; there was
increase in the counts of aerobes (such as Enterobacter and
Enterococcus) and anaerobes (such as Clostridium) and a decrease
in the count of Bifidobacterium. The severity of imbalance in gut
flora matched the degree of liver dysfunction, with the most
serious imbalance observed in patients in Child–Turcotte–Pugh
(CTP) class C. Liu et al.65 found that cirrhotic patients with MHE
had substantial derangements in the gut microecology, with sig-
nificant fecal overgrowth of potentially pathogenic Escherichia
coli and Staphylococcus species. Treatment with synbiotics sig-
nificantly increased the fecal content of non-urease-producing
Lactobacillus species at the expense of these other bacterial
species. Such modulation of gut flora was associated with a sig-
nificant reduction in blood ammonia levels and reversal of MHE in
50% of patients. Synbiotic treatment was also associated with a
significant reduction in endotoxemia. The CTP functional class
improved in nearly 50% of the patients.
Consensus statement
37 Ammonia plays a key role in the pathogenesis of MHE.
Ammonia has deleterious effects on brain metabolism and
neurotransmission. (1b)
38 Inflammation plays a synergistic role with ammonia in
modulating MHE. (1b)
39 Gut flora play an important role in the pathogenesis of
MHE. (3b)
40 There is substantial derangement in gut microecology with
significant fecal overgrowth of potentially pathogenic
Escherichia coli and Staphylococcus species in patients
with MHE. (3b)
41 Modulation of gut flora may lead to a significant reduction
in blood ammonia and endotoxin levels in patients with
MHE. (3b)
7. Natural history
The frequency of MHE increases as the severity of liver disease
increases.4,13–16,18,22 In view of a high frequency of MHE in patients
with liver disease, it is important to understand its impact on future
clinical outcomes, such as occurrence of overt HE, quality of life
and survival, and to determine whether treatment of MHE can
induce improvements in these outcomes.
Several studies that looked at the frequency of development of
overt HE in cirrhotic patients found that those with MHE devel-
oped overt HE more often during follow up than those without
MHE (Table 4).4,15,17,20,48,88,89 In addition, some studies have shown
an increased risk of death in patients with liver cirrhosis and MHE
compared to those without MHE (Table 4).20,22,88 However,
patients with MHE had poorer liver function than those without
MHE in these studies, making it difficult to ascribe the poor
outcome to the presence of MHE.
Das et al.4 studied the relationship of progression of MHE to
overt HE in relation to the severity of liver dysfunction and found
that the rate of progression to overt HE was much higher in
patients with MHE and a CTP score > 6 than in those with MHE
and a CTP score 6. Amodio et al.88 found that the presence of
MHE and that of liver dysfunction were both associated with
mortality on univariate analysis; however, on multivariate analysis,
liver functional status was the only independent predictor of mor-
tality. In another study, progression of MHE to overt HE was
associated with abnormal response to oral glutamine challenge,
which in turn was associated with poor liver function.90 Further-
more, MHE in patients with preserved liver function but large
portal-systemic shunts (congenital shunts, non-cirrhotic portal
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hypertension and cirrhosis with preserved liver function) appears
to have a good outcome, even though these data are based on a
small number of patients.10 Thus, it appears that the higher risk of
overt HE or death in patients with MHE may not be related to
MHE per se but to the poorer liver function in patients with
MHE.
Consensus statement
42 Patients with liver cirrhosis and MHE have a higher rate of
subsequent development of HE than those with cirrhosis
but no MHE. (1b)
43 Higher rate of development of overt HE and lower survival
amongst patients with MHE is most likely related to poorer
liver function in MHE patients. (1b)
44 Data on outcome of MHE in patients without liver disease
are limited and further prospective studies are needed. (5,
D)
8. Treatment
Treatment of MHE is primarily directed towards reduction of
ammonia and includes non-absorbable disaccharides, prebiotics/
probiotics and LOLA. Treatment of MHE improves psychometric
performance and quality of life (Table 5). However, several issues
regarding therapy remain unsettled. The effects of treating MHE
on driving, complex occupational tasks, development of overt HE,
and on survival have not been studied. Duration of therapy for
achieving these end-points, choice of therapeutic agents and the
role of combinations of therapies have also not been adequately
studied and further research is needed to clarify these issues.
8.1. Non-absorbable disaccharides
Lactulose decreases blood ammonia levels, and improves psycho-
metric performance and HRQOL (Table 5).3,59,62,64,67,91–95 Using
cerebral diffusion tensor imaging, Kale et al.59 showed that
interstitial brain edema observed in patients with MHE resolves
after treatment for 3 weeks with lactulose in parallel with improve-
ments in neuropsychiatric performance.
Prasad et al.3 studied the effect of treatment of MHE with lactu-
lose on psychometric performance (measured by NCT, FCT-A,
FCT-B, picture completion and block-design tests) and HRQOL
(measured by Sickness Impact Profile [SIP]). Patients with MHE
showed significant impairment in 11 scales of the SIP, the psycho-
social and physical subscores, and in the total SIP. Patients
received 30–60 mL of lactulose in two or three divided doses so
that the patient passed two to three semi-soft stools per day.
Following lactulose therapy for 3 months, both psychometric
performance and HRQOL improved; MHE reversed in 64.5% of
treated patients compared with 6.7% in the no-treatment group
(P < 0.0001). Significant improvement was found in five (emo-
tional behavior, ambulation, mobility, sleep/rest and recreation and
pastimes) of the 12 scales of the SIP and in the total psychosocial
and physical sub-scores in the treated patients compared with the
untreated patients. Improvement in HRQOL was linked to
improvement in cognitive function. A recent study that compared
lactulose, a probiotic and LOLA with no treatment, confirmed
Table 4 Results in studies on follow up of patients with and without minimal hepatic encephalopathy
Authors, year Number of patients
with/without MHE
Duration of follow up Results
Amodio et al.,88 1999 – Median 426 days On Kaplan–Meier analysis with log–rank test, patients
with abnormal psychometric tests had a significantly
higher rate of death (Scan test, HR 2.4 [95% CI
1.1-5.3]; Choice-2 test, HR 2.8 [1.2-6.3]).
Hartmann et al.,89 2000 25/91 – Overt HE: 40% vs 6.7%
Actuarial frequency of overt HE at 3 years: 56% in
patients with MHE vs 8% in those without. However,
occurrence of HE and death depended on CTP score
Saxena et al.,45 2001 28/51 Up to 16 months Overt HE: 42.8% vs 3.9%
Romero-Gomez et al.,15 2001 34/29 Up to 7 years Overt HE: 47.1% vs 10.3%, (P < 0.005)
Das et al.,4 2001 40/32 At least 6 months Overt HE in 22.6% vs 5.6% (P = 0.044) ) of patients
with and without MHE; rate higher in patients with
poorer liver function, as assessed by CTP score
Saxena et al.,17 2002 29/35 6–24 months Overt HE: 58.6% vs 5.7%
Romero-Gomez et al.,20 2007 35/79 Median 10.2 months Overt HE in 43.6% vs 17.3%; survival 27.3% vs 10.2%;
on multivariate analysis, CTP score was the only
independent predictor (HR 1.8 [1.32-2.46]; P = 0.0002).
Sharma et al.,10 2009 12/20 Mean 13.5 months None of the patients with or without MHE at baseline
developed HE in patients with EHPVO
Dhiman et al.,22 2009 48/52 Up to 30 months PHES 6 (HR 2.42 [1.01–5.77]) and CTP score  8 (HR
2.47; 95% CI, 1.01–6.02) had prognostic value for
survival.
CI, confidence interval; CTP, Child–Turcotte–Pugh; EHPVO, extrahepatic portal venous obstruction; HE, hepatic encephalopathy; HR, hazard ratio;
MHE, minimal HE; PHES, psychometric hepatic encephalopathy score.
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Table 5 Effect of treatment on various parameters in patients with minimal hepatic encephalopathy
Authors, year n Design of
the study
Therapy Duration of
therapy
Assessment tool(s) Results
McClain
et al.,91
1981
32 RCT Lactulose vs sucrose
(placebo)
– Psychometry Three of five psychometric tests showed
improvement in lactulose-treated
patients than in those receiving placebo.
Morgan
et al.,92
1989
14 RCT Lactulose vs lactitol 2 months NCT, DS, DC and EEG Improvement in psychometric
performance; no change in EEG mean
cycle frequency
Watanabe
et al.,931997
36 RCT Lactulose (n = 22) vs
no Rx (n = 14)
8 weeks NCT, DS, BD Improvement in psychometry, reversal of
MHE in 50% of patients in treated
group compared to 15% in untreated
group
Horsmans
et al.,94
1997
14 RCT Lactulose (n = 7) vs
lactose (n = 7)
15-day NCT, race track test and
computer-based
psychometry
Improvement in psychometric tests;
decline in blood ammonia levels
Dhiman
et al.,62
2000
26 RCT Lactulose (n = 14) vs
no Rx (n = 12)
3 months NCT, FCT, PC, BD Improvement in psychometry; reversal of
MHE in 57% of treated patients vs
none of untreated
Nie et al.,95
2003
66 RCT Lactulose (n = 45) vs
no Rx (n = 21)
8 to 24
weeks
NCT, DS, SEP and blood
ammonia
Improvement in blood ammonia and
psychometric tests; prevented
worsening of SEP and development of
overt HE
Kale et al.,59
2006
10 Case
series
Lactulose 3 weeks Diffusion tensor imaging,
psychometry (NCT, FCT,
PC, DS, PA, OA, BD)
Reversal of interstitial brain edema, which
correlated with improvement in
neuropsychiatric performance.
Dhiman
et al.,3 2007
61 RCT Lactulose (n = 31) vs
no treatment
(n = 30)
3 months NCT, FCT, PC, BD, SIP Lactulose led to significantly greater
improvement in psychometry and
HRQOL after 3 months (mean total SIP
score decreased from 10.39 [95% CI
9.36-11.43] to 3.77 [2.52-5.02] in treated
group vs from 10.36 [95% CI
8.98-11.73] to 10.39 [95% CI
8.36-12.42] in control group)
Mittal et al.,67
2009
90 RCT Lactulose (n = 23)
Probiotics (n = 23)
LOLA (n = 22)
Placebo (n = 22)
3 months NCT, FCT, PC, BD, SIP Compared to no treatment, lactulose,
probiotics and LOLA led to significantly
greater improvement in blood ammonia
levels, psychometry scores and
HRQOL.
Liu et al.,65
2004
55 RCT Fermentable fiber
(n = 20), probiotic
(n = 20), or
placebo (n = 15)
30 days NCT, BAEP Synbiotic treatment led to increased fecal
content of non-urease-producing
Lactobacillus species, reduction in
endotoxemia and blood ammonia levels;
reversal of MHE and improvement in
CTP class in 50% of patients.
Malaguarnera
et al.,66
2007
60 RCT Synbiotic (n = 30)
Placebo (n = 30)
90 days Psychometry,
automated EEG analysis
Improvement in blood ammonia levels and
psychometry scores in symbiotic
treated group.
Bajaj et al.,63
2008
35 RCT Probiotic yogurt
(n = 17) vs no
intervention (n = 8)
60 days NCT A, BD, DS; SF 36 MHE reversed in 71% patients of yogurt
patients compared with no patients
without intervention.
None of the former vs 25% of the latter
developed overt HE. No change in SF
36 score.
BAEP, brainstem auditory evoked potential; CTP, Child–Turcotte–Pugh; BD, block design; DC, digit copying; DS, digit symbol test; EEG, electroen-
cephalogram; FCT, figure connection test; HRQOL, health related quality of life; LOLA, L-ornithine–L-aspartate; NCT, number connection test; OA,
object assembly; PA, picture arrangement; PC, picture assembly; RCT, randomized controlled trial; Rx, treatment; SEP, sensory evoked potential; SF
36, short form 36; SIP, sickness impact profile.
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these findings.67 Lactulose or lactitol, both non-absorbable, syn-
thetic disaccharides with multiple effects on gut flora, are regarded
as intestinal prebiotics.96 Dietary addition of lactulose can exert a
bifidogenic effect accompanied by a favorable effect on colonic
NH3 metabolism.97
A meta-analysis of randomized trials of lactulose versus placebo
or no intervention in treatment of patients with MHE showed that
the treatment with lactulose was associated with improvement in
psychometric (cognitive) performance.35
8.2. Prebiotics, probiotics or synbiotics
Prebiotics, probiotics or synbiotics (probiotics and fermentable
fiber) are effective in treating patients with MHE,63–67 and can also
be used as long-term therapy. Liu et al.65 showed that modulation of
gut microecology and acidification of gut lumen in patients with
liver cirrhosis and MHE by treatment with synbiotics resulted in
increased fecal content of non-urease-producing Lactobacillus
species, whereas the number of urease-producing pathogenic
Escherichia coli and Staphylococcal species decreased. This effect
persisted for 14 days after cessation of supplementation. It was
associated with a significant reduction in blood ammonia and
endotoxin levels and reversal of MHE in nearly 50% of the patients.
The severity of liver disease, as assessed according to CTP class,
also improved in nearly 50% of the patients. In a recent randomized
control trial, supplementation with probiotic yogurt resulted in a
significant reversal of MHE in the group receiving yogurt compared
to no treatment.63 Treatment with a probiotic preparation also
improves HROQL.67 Prebiotics, probiotics or synbiotics are effica-
cious in the treatment of HE by decreasing bacterial urease activity,
pH in the gut lumen, ammonia absorption and total ammonia in the
portal blood, and by improving nutritional status of gut epithelium
resulting in decreasing intestinal permeability. In addition, they
help ameliorate the inflammation and oxidative stress in the hepa-
tocytes, leading to increased hepatic clearance of ammonia.98 These
mechanisms may be additive or synergistic in treating MHE. Pro-
biotics may represent a safe, effective, long-term therapy for MHE
and may be an alternative to lactulose.
8.3. L-ornithine–L-aspartate
Clinical studies evaluating the role of LOLA in the treatment of
MHE did not show its effectiveness; however, these studies were
small and underpowered. A recent study that compared lactulose,
a probiotic and LOLA with no treatment, however, showed that
LOLA is as effective as lactulose or a probiotic preparation in
improving psychometric performance and HRQOL.67 Larger pro-
spective studies are warranted to evaluate the role of LOLA before
it can be recommended for the treatment of MHE.
8.4. Antibiotics
The role of antibiotics in MHE has not been evaluated. Prospective
studies with poorly absorbed antibiotics are required to evaluate
their efficacy in improving MHE.
Consensus statement
45 Lactulose is effective in reducing blood ammonia levels
and improving psychometric performance in cirrhotic
patients with MHE. (1b)
46 Lactulose improves HRQOL in cirrhotic patients with
MHE. (1b)
47 Treatment may be initiated with lactulose; patients with
MHE should receive 30–60 mL of lactulose in two or three
divided doses to achieve two to three semi-soft stools per
day. Treatment should be continued for 3–6 months. (1b, A)
48 Probiotics are effective in improving ammonia levels and
psychometric performance in patients with liver cirrhosis
and MHE. (1b)
49 Probiotics improves endotoxemia and Child–Turcotte–
Pugh functional class in patients with liver cirrhosis and
MHE. (1b)
50 Probiotics also improve HRQOL in patients with liver cir-
rhosis and MHE. (1b)
51 Optimum doses of probiotic preparations have not been
established. Prospective randomized controlled trials are
required to determine the effectiveness of various doses.
(5, D)
52 A single study has shown that LOLA is as effective as
lactulose or a probiotic preparation in improving psycho-
metric performance and HRQOL. Further adequately
powered, prospective, randomized controlled trials are
needed to assess the effectiveness of LOLA in the treatment
of MHE. (1b,A)
53 The role of antibiotics in the treatment of MHE has not
been evaluated till now. Prospective randomized controlled
trials to determine the effectiveness of poorly absorbed
antibiotics for treatment of MHE are required. (5, D)
54 The effect of treatment of MHE on the prevention of devel-
opment of overt HE, on driving, complex occupational
Figure 1 Algorithm for diagnosis and treatment of cirrhotic patients
with minimal hepatic encephalopathy. *Any of the test(s) can be used
depending upon the availability of control values. BD, block design; CFF,
critical flicker frequency; DS, digit symbol; FCT, figure connection test;
ICT, inhibitory control test; MHE, minimal hepatic encephalopathy;
MMSE, Mini-Mental State Examination; NCT, number connection test;
PHES, Psychometric Hepatic Encephalopathy Score.
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tasks and on survival has not been studied. Prospective
randomized controlled studies are needed. (5, D)
9. Algorithm for diagnosis
and treatment
The INASL Working Party recommends that all patients with
cirrhosis be screened for the presence of MHE using a standard
battery of psychometric tests, PHES, CFF or ICT, depending upon
the availability of tests and their validation for local populations
from different parts of the world (Fig. 1). Patients whose index
psychometric or computerized test results do not indicate pathol-
ogy should be screened every 6–12 months. Treatment for MHE
may be initiated with lactulose; patients should receive 30–60 mL
of lactulose in two or three divided doses so that they pass two to
three semi-soft stools per day. Although the appropriate duration
of therapy for MHE is unsettled, at least three studies suggest that
treatment may be advised for 3–6 months.3,67,95
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